ReportsnReports.

com adds report Identifying and Commercializing First-in-Class Innovation in Non-

Small-Cell Lung Carcinoma to its store.

Large Degree of Innovation in NSCLC Pipeline

The NSCLC pipeline currently has 389 products in active development across all stages, but a stark
contrast between the mechanisms of action employed in the current market and the pipeline is evident.
Where the market comprises primarily ineffective chemotherapies that target tubulin or DNA
replication, the pipeline shows an incredibly diverse range of therapies targeting multiple signaling
pathways and molecules integral to cancer development. This diversity is partially due to the presence
of 122 first-in-class products, which accounts for 38% of the overall pipeline therapies that disclosed
their target. In an industry, market and development landscape that favors first-in-class over non-first-
in-class development in many ways, such as through faster approval or greater revenue, this finding has
strategic implications for a wide array of market participants, both large and small. Despite a high
attrition rate in NSCLC, first-in-class therapies that reach the market have the potential to transform and
improve the NSCLC treatment landscape.

Alignment of First-in-Class Molecular Target with Disease Causation

The method of characterizing NSCLC tumors is currently shifting from the traditional histology-based
characterization to a more specific molecule-based method of characterization. This has resulted in the
identification of key oncogenic mutations in NSCLC and has coincided with the rise of targeted pipeline
therapies, which are designed to target proteins in signaling pathways that are frequently mutated,
amplified or overexpressed in NSCLC. Aligning the molecular target with disease-causing signaling
pathways and frequently mutated pathways therapies can benefit from reduced systemic cytotoxic
effects while still inhibiting tumor-promoting signaling. Therefore, targeted therapies often display
superior safety and efficacy to chemotherapies.

Complete report available @ http://www.reportsnreports.com/reports/312767-identifying-and-
commercializing-first-in-class-innovation-in-non-small-cell-lung-carcinoma.html .

GBI Researchs proprietary analysis showed substantial variation in how well NSCLC first-in-class targets
align to frequent gene mutations. Further in-depth analysis identified the most promising first-in-class
targets based on various scientific and clinical parameters. Examining scientific and clinical data of
promising first-in-class targets showed that first-in-class status is not, in its own right, enough for a
successful product; however, the first-in-class products substantiated by scientific and clinical evidence
will be exciting future prospects with the potential to transform the NSCLC market.

First-in-Class Products in Licensing and Co-development Deals

The NSCLC deals landscape appears relatively quiet for such a large indication. However, analysis
showed that of the therapies with disclosed deal values there is significant range in the value of NSCLC
deals. Concerning first-in-class specifically, only five licensing or co-development deals have been made
since 2006. Despite the low sample size, it is clear that the first-in-class NSCLC products offer an
attractive investment prospect as they command much higher deal values and, on average, deals occur
earlier in development compared to non-first-in-class counterparts. Both trends were substantiated by
industry-wide data that showed that, particularly in Phase I, first-in-class products would attract larger
mean and median total deal values. The data highlight that the first-in-class deals landscape is different
and indicates a greater chance of becoming much more lucrative than the deals landscape for addition-
to-class or advance-in-class therapies.

A total of 117 first-in-class products that are currently in development have not yet been entered into a
licensing or co-development deal. In a transforming market that will favor innovative, targeted therapies
with a strong clinical record, there are numerous opportunities for strategic alliances to bolster a first-in-
class portfolio or fund clinical development. Although not all are aligned to disease-causing signaling
pathways, many are supported by robust scientific and clinical data, making them attractive prospects
as both therapeutics and investment opportunities.

Scope

The report analyzes innovation in NSCLC in the context of the overall pipeline and current market
landscape. It also analyzes the deals landscape surrounding first-in-class products and pinpoints in-
licensing opportunities.

The report includes:

A brief introduction to NSCLC, including symptoms, pathophysiology, and an overview of
pharmacotherapy and treatment algorithms
Extensive categorization of histological and molecular features of NSCLC tumors
Coverage of the changing molecular target landscape and particular points of innovation in the
pipeline
A comprehensive review of the pipeline for first-in-class therapies, analyzed by stage of
development, molecule type and molecular target
Identification and assessment of first-in-class molecular targets with a particular focus on early-
stage programs of which clinical utility has yet to be evaluated, as well as literature reviews of
novel molecular targets
Industry-wide analysis of first-in-class deals compared to non-first-in-class deals
An assessment of the licensing and co-development deal landscape for NSCLC therapies and
benchmarking of deals comparing first-in-class and non-first-in-class-products

Inquire for Discount @ http://www.reportsnreports.com/contacts/discount.aspx?name=312767 .
(This is a premium report priced at US$6995 for a single user PDF.)

Reasons To Buy

The report will enable business development and enable marketing executives to strategize their
product launches by allowing them to:

Understand the focal shifts in molecular targets in the NSCLC pipeline
Understand the distribution of pipeline programs by phase of development, molecule type and
molecular target
Access a scientific and clinical analysis of first-in-class developmental programs for NSCLC,
benchmarked against non-first-in-class targets
Assess the valuations of licensed and co-developed NSCLC treatments
Access a list of the first-in-class therapies potentially open to deal-making opportunities

List of Figures

Figure 1: Innovation Trends in Product Approvals
Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Product post Marketing Approval
Figure 3: Molecular Characteristic Frequency (%)
Figure 4: Non-Squamous Stage IIIB/IV Treatment Algorithm
Figure 5: Squamous Stage IIIB/IV Treatment Algorithm
Figure 6: Molecule Types in Marketed Products
Figure 7: Targets in Marketed Products
Figure 8: DNA Synthesis/Repair Targets
Figure 9: Efficacy and Safety Heatmap of Marketed Products
Figure 10: Developmental Pipeline Overview
Figure 11: Receptor Tyrosine Kinase Molecular Targets
Figure 12: Molecular Target Category Comparison, Pipeline and Marketed Products
Figure 13: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular
Targets
Figure 14: First-in-Class Products in the Pipeline, Part 1
Figure 15: First-in-Class Products in the Pipeline, Part 2
Figure 16: Signaling networks of functional families in NSCLC
Figure 17: Signaling network of multi-process functional proteins in NSCLC
Figure 18: First-in-Class Molecular Target Analysis Matrix (Part 1)
Figure 19: First-in-Class Molecular Target Analysis Matrix (Part 2)
Figure 20: Data and Evidence for PTK2 as a Therapeutic Target
Figure 21: Pipeline Programs Targeting PTK2
Figure 22: Data and Evidence for Erbb3 as a Therapeutic Target
Figure 23: Pipeline Programs Targeting ErbB3
Figure 24: Data and Evidence for TP53 as a Therapeutic Target
Figure 25: Pipeline Programs Targeting P53
Figure 26: Data and Evidence for CD274 as a Therapeutic Target
Figure 27: Pipeline Programs Targeting CD274
Figure 28: Data and Evidence for Akt2 as a Therapeutic Target,
Figure 29: e Programs Targeting Akt2
Figure 30: Data and Evidence for STAT3 as a Therapeutic Target
Figure 31: Pipeline Programs Targeting STAT3
Figure 32: Data and Evidence for FGF1 as a Therapeutic Target
Figure 33: Pipeline Programs Targeting FGF1
Figure 34: Data and Evidence for CDK4 as a Therapeutic Target
Figure 35: Pipeline Programs Targeting CDK4
Figure 36: Data and Evidence for AURKB as a Therapeutic Target
Figure 37: Pipeline Programs Targeting AURKB
Figure 38: Data and Evidence for FNTA as a Therapeutic Target
Figure 39: Pipeline Programs Targeting FNTA
Figure 40: Data and Evidence for CHEK1 as a Therapeutic Target
Figure 41: Pipeline Programs Targeting CHEK1
Figure 42: Data and Evidence for HIF1A as a Therapeutic Target
Figure 43: Pipeline Programs Targeting HIF1A
Figure 44: Data and Evidence for DKK1 as a Therapeutic Target
Figure 45: Pipeline Programs Targeting DKK1
Figure 46: Industry Wide Deals by Stage of Development, 20062014
Figure 47: Industry Licensing Deal Values by Stage of Development, 2006-2014
Figure 48: Licensing Agreements, 20062014
Figure 49: First-in-Class and Non-First-in-Class Deals Comparison, 20062014
Figure 50: Regional Network of Licensing Agreements, 20062014
Figure 51: Licensing Agreements by Molecule Type, 20062014
Figure 52: Licensing Agreements by Mechanism of Action, 20062014
Figure 53: Summary of Licensing Deals, 20062014
Figure 54: Co-development Deals by Year and Phase, 20062014
Figure 55: Regional Network of Co-development Deals, 20062014
Figure 56: Co-development Deals by Molecule Type, 20062014
Figure 57: Co-development Deals by Mechanism of Action, 20062014
Figure 58: Summary of Co-development Deals, 20062014
Figure 59: First-in-class Programs with no Recorded Prior Deal Involvement, 20062014 (Part 1)
Figure 60: First-in-class Programs with no Recorded Prior Deal Involvement, 20062014 (Part 2)

Purchase a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=312767 .

About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes
450,000+ market research reports from over 95 leading global publishers & in-depth market research
studies of over 5000 micro markets. We offer you customization options on reports by & custom reports
through MarketsandMarkets.com. With comprehensive information about the publishers and the
industries for which they publish market research reports, we help you in your purchase decision by
mapping your information needs with our huge collection of reports.